



MAGEA6 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP6168a

Specification

MAGEA6 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession P43360
Other Accession NP 005354

MAGEA6 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 4105

Other Names

Melanoma-associated antigen 6, Cancer/testis antigen 16, CT16, MAGE-6 antigen, MAGE3B antigen, MAGEA6, MAGE6

Target/Specificity

The synthetic peptide sequence is selected from the C-terminus of human MAGEA6.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MAGEA6 Antibody (C-term) Blocking Peptide - Protein Information

Name MAGEA6

Synonyms MAGE6

Function


Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing

MAGEA6 Antibody (C-term) Blocking Peptide - Background

MAGEA6 is a member of the MAGEA gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 80% sequence identity between each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are expressed at a high level in a number of tumors of various histologic types, and are silent in normal tissues with the exception of testis and placenta. The MAGEA genes are clustered on chromosome Xq28. They may be implicated in some hereditary disorders, such as dyskeratosis congenita.

MAGEA6 Antibody (C-term) Blocking Peptide - References

Tatsumi, T., et al., Clin. Cancer Res. 9(3):947-954 (2003).Tatsumi, T., et al., J. Exp. Med. 196(5):619-628 (2002).lmai, Y., et al., Gene 160(2):287-290 (1995).Rogner, U.C., et al., Genomics 29(3):725-731 (1995).De Plaen, E., et al., Immunogenetics 40(5):360-369 (1994).





E3 ubiquitin-protein ligases. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines.

Tissue Location

Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes

MAGEA6 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides